FDA Approves Uplizna for Generalized Myasthenia Gravis,Targeting B Cells in Novel Approach
Table of Contents
The Food and Drug administration has approved Uplizna (inebilizumab-cdon) for adults living with anti-acetylcholine receptor and anti-muscle specific tyrosine kinase antibody positive generalized myasthenia gravis (gMG),offering a new treatment option for a debilitating autoimmune disease. The approval, announced December 12, 2025, marks a significant advancement in gMG management, particularly as the first and only therapy specifically targeting CD19-positive B cells.
A New Paradigm in gMG treatment
gMG is an autoimmune disorder characterized by muscle weakness, impacting critical functions like breathing, swallowing, speech, and vision.The approval of Uplizna stems from the positive results of the phase 3 MINT trial, published in the New England Journal of Medicine and led by Richard Nowak, MD, MS, director of the Myasthenia Gravis Clinic at Yale University, and his colleagues.
The study enrolled 238 patients with gMG and demonstrated that Uplizna significantly outperformed placebo in improving patients’ daily lives. At 26 weeks,individuals receiving inebilizumab-cdon showed a greater enhancement from baseline in their Myasthenia Gravis Activities of Daily Living (MG-ADL) scale scores – a key measure of functional ability. Improvements were also observed in the Quantitative Myasthenia Gravis scale.
“Throughout my years working with people living with myasthenia gravis, I have seen how profoundly this condition can impact daily life,” Nowak stated. “This FDA approval reflects years of dedicated research and a commitment to addressing the ongoing needs of patients.”
Targeting the Root Cause of gMG
Uplizna’s mechanism of action sets it apart from existing treatments.By targeting CD19-positive B cells – including plasmablasts and long-lived plasma cells – the therapy addresses a key source of the disease. These B cells are responsible for producing the pathogenic autoantibodies that attack the neuromuscular junction in gMG.
“As the first-and-only FDA-approved therapy that targets CD19+ B cells, Uplizna offers a fundamentally new way to approach the disease,” Nowak explained. “Targeting B cells, among them plasmablasts and long-lived plasma cells – the B-cell ‘factories’ that produce pathogenic AChR and MuSK autoantibodies – Uplizna addresses gMG at a key source.”
The therapy’s unique mechanism,coupled with its durable efficacy and convenient twice-yearly dosing schedule,has the potential to significantly improve long-term disease management for patients.
Disclosures and Source Data
the approval is based on a press release issued by Amgen. Nowak disclosed grant and contractor roles with Alexion Pharmaceuticals, Amgen, Argenx, Grifols Therapeutics, Horizon Therapeutics, Immunovant, Janssen Pharmaceuticals, Myasthenia Gravis Foundation of america, National Institutes of He
